TORUS I Clinical Study

Peripheral Arterial Disease Clinical Trial

Official title:

Long Segment Lesion Peripheral Artery Revascularization Feasibility Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03128424
• Other study ID #: STP 185
• Status: Active, not recruiting
• Phase: N/A
• Start date: March 2016
• Est. completion date: July 2021

Study information

• Verified date: October 2020
• Source: PQ Bypass, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the feasibility study is to evaluate the safety and effectiveness of the PQ Bypass Stent Graft System in the treatment of atherosclerotic lesions of the native superficial femoral artery (SFA) or the superficial femoral and proximal popliteal arteries.

Description:

The primary safety endpoint for this study is freedom from a major adverse event (MAE) at 30 days post-procedure. An MAE is defined as TLR, amputation of the treated limb or death.

The primary effectiveness endpoint is defined as stent patency as evidenced by a peak systolic velocity ratio (PSVR) < 2.5 from DUS obtained within the 12-month visit window with no clinically-driven re-intervention within the stented segment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: July 2021
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Age = 18 years and of age of legal consent.

2. Women of child bearing potential must have a negative pregnancy test within 7 days prior to the index procedure.

3. Subject has lifestyle limiting claudication or rest pain (Rutherford Becker scale 2-4) with a resting ABI < 0.9. Resting TBI is utilized only if unable to reliably assess ABI. TBI must be <0.7. These assessments are required for the target limb, but both limbs are preferred.

4. A superficial femoral artery lesion with >50% stenosis or occlusion which requires treatment.

5. Stenotic lesion(s) or occluded length within the same vessel (one long or multiple serial lesions) = 120mm to < 200mm.

6. Reference vessel diameter (RVD) = 5.0mm and = 6.7 mm, angiographically/CTA/MRA defined.

7. Patent popliteal artery 3 cm proximal to tibial plateau

8. At least 1 patent tibial artery to the foot (<50% stenosis)

9. The target lesion(s) can be successfully crossed with a guide wire and dilated.

10. Poor aortoiliac or common femoral "inflow" (i.e. angiographically defined >50% stenosis of the iliac or common femoral artery) that would be deemed inadequate to support a successful treatment of the target lesion without prior treatment. Adequate aortoiliac or common femoral "inflow" is defined as <30% stenosis after either PTA or stenting of the inflow lesion. After treatment of the inflow lesion, the residual pressure gradient across the target lesion will be obtained and if the peak to peak pressure gradient is < 20mmHg, the subject will be included in the study.

11. A subject with bilateral obstructive SFA disease is eligible for enrollment into the study. The contra-lateral procedure should not be done until at least 30 days after the index procedure (staged); however, if contra-lateral treatment is performed prior to treatment of the target lesion, the waiting period will be at least 30 days prior to the index procedure.

12. The subject is eligible for standard surgical repair, if necessary.

13. A subject who requires a coronary intervention should have it performed at least 30 days prior or 30 days post the treatment of the target lesion.

14. Subject must provide written informed consent.

15. Subject must be willing to comply with the specified follow-up evaluation schedule.

Exclusion Criteria:

1. Age greater than 90

2. Thrombophlebitis or deep venous thrombus, within the previous 30 days.

3. Receiving dialysis or immunosuppressant therapy within the previous 30 days.

4. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.

5. Stroke within the previous 90 days.

6. Ipsilateral femoral aneurysm or aneurysm in the SFA or popliteal artery.

7. Required stent placement via a popliteal approach.

8. Procedures which are pre-determined to require stent-in-stent placement to obtain patency, such as in-stent restenosis.

9. Significant vessel tortuosity or other parameters prohibiting access to the lesion or 90° tortuosity which would prevent delivery of the stent device.

10. Required stent placement within 1 cm of a previously deployed stent.

11. Known allergies to any of the following: aspirin and clopidogrel bisulfate (Plavix®), ticlopidine (Ticlid ®),and prasugrel (Effient®); heparin; Nitinol (nickel titanium); or contrast agent, that cannot be medically managed.

12. Presence of thrombus prior to crossing the lesion.

13. Known or suspected active infection at the time of the procedure.

14. Use of cryoplasty, laser, or atherectomy devices in the target vessel at the time of index procedure.

15. Restenotic lesion that had previously been treated by atherectomy, laser or cryoplasty within 3 months of the index procedure.

16. History of neutropenia, coagulopathy, or thrombocytopenia that was unexplained or is considered to be at risk for reoccurrence.

17. Known bleeding or hypercoagulability disorder or significant anemia (Hb<8.0) that cannot be corrected.

18. Subject has the following laboratory values: a. platelet count less than 80,000/µL, b. international normalized ratio (INR) greater than 1.5, c. serum creatinine level greater than 2.0 mg/dL.

19. Subject requires general anesthesia for the procedure.

20. Major distal amputation (above the transmetatarsal) in the study or non-study limb.

21. Patient has had a revascularization procedure on the target limb within 30 days of the planned index procedure

22. Patient has a planned amputation of the target limb

23. Previous bypass surgery on the target limb

24. Subject is pregnant or plans to become pregnant during the study.

25. Subject has a co-morbid illness that may result in a life expectancy of less than 1 year.

26. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening other than a PQ Bypass study.

NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now CE marked product are not excluded by this criterion.

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• PQ Bypass Stent Graft System
The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
PQ Bypass, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	freedom from a major adverse event (MAE)	An MAE is defined as target lesion revascularization (TLR), amputation of the treated limb or death.	30 days
Secondary	Major adverse vascular event (MAVE)	Major adverse vascular event (MAVE) at 30 days, 6 months and 12 months defined as stent thrombosis, target limb amputation, clinically apparent distal embolization, defined as causing end-organ damage (e.g. lower extremity ulceration, tissue necrosis, or gangrene), procedure related arterial rupture, acute limb ischemia or bleeding event requiring transfusion.	30 days, 6 months, 12 months
Secondary	Technical Success	Acute technical successdefined as : successful delivery, access and placement of the investigation devies and successful removal of the delivery system	Procedure
Secondary	Improvement in Ankle Brachial Index	ABI	1, 6, and 12 months
Secondary	Lesion Success	Target vessel revascularization (TVR)	6 and 12 months